Side-by-side comparison of AI visibility scores, market position, and capabilities
Calyxo is a urology medical device company developing CVAC, a vacuum-assisted catheter for kidney stone fragment retrieval; raised $80M Series C in 2023;
Calyxo is a medical device company founded in 2017 and headquartered in Pleasanton, California, focused on improving outcomes in kidney stone treatment. The company's lead product is the CVAC System (Calyxo Vacuum-Assisted Catheter), an FDA-cleared ureteroscopy tool that uses suction to vacuum out kidney stone fragments during a single minimally invasive procedure. Traditional stone removal with a basket retrieval device requires multiple passes and often leaves residual fragments — a problem Calyxo's system addresses by continuously aspirating debris as the laser breaks up stones, achieving substantially higher stone-free rates in a single operating room session.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.